ArticleVirchows Archiv : an international journal of pathology2010
Differential expression of glu-tubulin in relation to mammary gland disease.
Article in Virchows Archiv : an international journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Mechanisms of Chromosome Congression during Mitosis.Biology · 2017Review
- The Tubulin Code: A Navigation System for Chromosomes during Mitosis.Trends in cell biology · 2016Review
- Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment.Cancer research · 2014Article
- Interplay of Stem Cell Characteristics, EMT, and Microtentacles in Circulating Breast Tumor Cells.Cancers · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tubulin is one of the molecular components that regulate cytosketal structure relating to cell differentiation, invasion, and metastasis in cancer. Recently, glu-tubulin, in which the C-terminal tyrosine of α-tubulin is removed by tubulin carboxypeptidase, overexpression has been reported in malignant tumors of the mammary gland immunohistochemically. We identified 147 cases accessioned in the Department of Pathology, International University of Health and Welfare Hospital from 2003 to 2009. Of the 78 malignant tumor cases, staining for glu-tubulin was observed in 56 (71.8%), and only 22 cases showed no significant staining. However, in benign disease, glu-tubulin staining was detected in the cytoplasm of fibroblasts and endothelial cells, but was completely absent from epithelial cells in 64 of 69 cases. When the expression of glu-tubulin was compared between malignant tumor, benign tumor, and other benign disease, a significant differentiation was found among expressions of this protein. These results indicate that glu-tubulin represents a strong selective expression for cancer cells and may be useful to identify and quantify human breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.